Adverse effects: 1b. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks) | ||||
---|---|---|---|---|
Study | Intervention | Mean | SD | N |
average endpoint score of AIMS | ||||
Yagcioglu 2005 | Risperidone | 1.3 | 0.88 | 16 |
Yagcioglu 2005 | Placebo | 1.0 | 0.86 | 14 |
average change score of Barnes akathisia rating scale | ||||
Honer 2006 | Risperidone | 0.5 | 0.7 | 32 |
Honer 2006 | Placebo | 0.4 | 0.8 | 33 |
Yagcioglu 2005 | Risperidone | 0.18 | 0.6 | 16 |
Yagcioglu 2005 | Placebo | 0.72 | 0.6 | 14 |
average change score of ESRS | ||||
Honer 2006 | Risperidone | 9.3 | 6.9 | 32 |
Honer 2006 | Placebo | 7.8 | 7.0 | 32 |
average change score of ESRS ‐ dystonia | ||||
Honer 2006 | Risperidone | 0.2 | 0.7 | 32 |
Honer 2006 | Placebo | 0.1 | 0.5 | 33 |
average change score of ESRS ‐ dyskinesia | ||||
Honer 2006 | Risperidone | 2.4 | 4.1 | 32 |
Honer 2006 | Placebo | 2.1 | 4.2 | 33 |
average change score of ESRS ‐ parkinsonism | ||||
Honer 2006 | Risperidone | 6.7 | 4.3 | 32 |
Honer 2006 | Placebo | 5.5 | 4 | 32 |